Prof. Vahit Ozmen

Istanbul University, Turkey

Email: [email protected]

Qualifications

1978 M.D., Istanbul Unıversity, Turkey

Publications (Selected)

1. Özkurt, E., Ordu, C., Özmen, T., Ilgun, A. S., Soybir, G., Celebi, F., ... & Ozmen, V. (2025). Vitamin D supplementation during neoadjuvant chemotherapy for breast cancer improves pathological complete response: a prospective randomized clinical trial. World Journal of Surgery, 49(6), 1396-1405.
2. Ozmen, T., Bouche, C., Buttignol, M., Arboleda-Osorio, B., Costa, M. M., Coudane, H., ... & Mathelin, C. (2025). What Changes are Mandatory in Breast Surgery Training? An International Survey and Recommendations of the French Academy of Surgery and the Senologic International Society. European Journal of Breast Health, 21(3), 200.
3. Cabıoğlu, N., Koçer, H. B., Karanlık, H., Gülçelik, M. A., Iğci, A., Müslümanoğlu, M., ... & Özmen, V. (2025). De-escalation of nodal surgery in clinically node-positive breast cancer. JAMA surgery, 160(3), 257-266.
4. Cabioglu, N., Karanlik, H., Igci, A., Muslumanoglu, M., Gulcelik, M. A., Uras, C., ... & Ozmen, V. (2025). Breast cancer recurrence in initially clinically node-positive patients undergoing sentinel lymph node biopsy after neoadjuvant chemotherapy in the NEOSENTITURK-trials MF18-02/18-03. Annals of Surgical Oncology, 32(2), 952-966.
5. Ozcinar, B., Aribal, E., Cabioglu, N., Gurdal, S. O., Varol, G., Akyurt, N., ... & Ozmen, V. (2025). Long-term outcomes of Türkiye’s first population-based mammography screening program: a decade of breast cancer detection and survival analysis in Bahçeşehir. BMC Women's Health, 25(1), 5.
6. Muslumanoglu, M., Cabioglu, N., Igci, A., Karanlık, H., Kocer, H. B., Senol, K., ... & Ozmen, V. (2025). Combined analysis of the MF18‐02/MF18‐03 NEOSENTITURK studies: ypN‐positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided. Cancer, 131(1), e35610.
7. Muslumanoglu, M., Mollavelioglu, B., Cabioglu, N., Emiroglu, S., Tukenmez, M., Karanlık, H., ... & Igci, A. (2024). Axillary lymph node dissection is not required for breast cancer patients with minimal axillary residual disease after neoadjuvant chemotherapy. World journal of surgical oncology, 22(1), 286.
8. Seker, M. E., Koyluoglu, Y. O., Ozaydin, A. N., Gurdal, S. O., Ozcinar, B., Cabioglu, N., ... & Aribal, E. (2024). Diagnostic capabilities of artificial intelligence as an additional reader in a breast cancer screening program. European Radiology, 34(9), 6145-6157.
9. Cabioglu, N., Onder, S., Karatay, H., Bayram, A., Oner, G., Tukenmez, M., ... & Yavuz, E. (2024). New emerging chemokine receptors: CCR5 or CXCR5 on tumor is associated with poor response to chemotherapy and poor prognosis in locally advanced triple-negative breast cancer. Cancers, 16(13), 2388.
10. Bahçacı, U., Atasavun Uysal, S., Erdogan İyigün, Z., Ordu, Ç., Soybir, G. R., & Ozmen, V. (2024). Progressive relaxation training in patients with breast cancer receiving aromatase inhibitor therapy-randomized controlled trial. Plos one, 19(4), e0301020.
11. Kurt, S., Ilguen, A. S., Özkurt, E., Soybir, G., Alço, G., Ünal, Ç., ... & Özmen, V. (2024). Outcomes of reconstructive techniques in breast cancer using BCCT. core software. World Journal of Surgical Oncology, 22(1), 82.
12. Ünal, Ç., Özmen, T., İlgün, A. S., Ordu, Ç., Özkurt, E., Ak, N., ... & Özmen, V. (2023). MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification. Breast Cancer: Targets and Therapy, 659-669.
13. Ünal, Ç., Ordu, Ç., Özmen, T., İlgun, A. S., Çelebi, F., Baysal, B., ... & Özmen, V. (2023). Evaluation of anti-Mullerian hormone levels, antral follicle counts, and mean ovarian volumes in chemotherapy-induced amenorrhea among breast cancer patients: A prospective clinical study. Current Oncology, 30(10), 9217-9229.
14. Agiannitopoulos, K., Pepe, G., Tsaousis, G. N., Potska, K., Bouzarelou, D., Katseli, A., ... & Nasioulas, G. (2023). Copy number variations (CNVs) account for 10.8% of pathogenic variants in patients referred for hereditary cancer testing. Cancer genomics & proteomics, 20(5), 448-455.
15. Cabioglu, N., Bayram, A., Emiroglu, S., Onder, S., Karatay, H., Oner, G., ... & Ozmen, V. (2023). Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer. Frontiers in oncology, 13, 1165257.
16. Ozmen, T., & Ozmen, V. (2023). Treatment changes in breast cancer management and de-escalation of breast surgery. European journal of breast health, 19(3), 186.

Profile Details

WoS ResearcherID: AAE-3904-2020

https://orcid.org/0000-0003-2973-8247

https://vahitozmen.com/

https://scholar.google.com/citations?user=Fe_7IKsAAAAJ&hl=tr

https://www.researchgate.net/profile/Vahit-Ozmen